Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

The Food and Drug Administration (FDA) black box warning on oral sodium phosphates (OSPs) came late last year, but as early as 2003, doctors were beginning to make the link between OSP pills and solutions used to clear the bowel before colonoscopies and serious and permanent kidney injuries. As more and more reports of kidney damage and even complete kidney failure began to pour in to the FDA, the agency finally issued a mild warning in 2005. The black box warning on prescription OSP products would come three years later, after 21 more reports of serious kidney injuries. Soon after that FDA warning, C.B. Fleet quickly pulled its over-the-counter OSP products off the market.

Read the rest of this entry »

Maker of bowel cleansing products and laxatives C.B. Fleet wants to sell its over-the-counter oral sodium phosphate (OSP) solutions to consumers even though the company recalled them six months ago after the Food and Drug Administration (FDA) issued black box warnings on prescription OSPs and raised serious concerns over the over-the-counter OSP products. The FDA had received numerous reports of a serious form of kidney injury known as acute phosphate nephropathy following the use of OSP.

Read the rest of this entry »